Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

Mark Lipstein; Owen O'Connor; Francesca Montanari; Luca Paoluzzi; Danielle Bongero; Govind Bhagat

doi:10.3816/CLML.2010.n.074

Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

Mark Lipstein, Owen O'Connor, Francesca Montanari, Luca Paoluzzi, Danielle Bongero, Govind Bhagat

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

Original language	English (US)
Pages (from-to)	E43-E46
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	10
Issue number	5
DOIs	https://doi.org/10.3816/CLML.2010.n.074
State	Published - Oct 2010
Externally published	Yes

Keywords

Diffuse large B-cell lymphoma
Non-Hodgkin lymphoma
R-CHOP

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3816/CLML.2010.n.074

Cite this

@article{d18538492ce74dd191990303d80f4731,

title = "Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma",

abstract = "Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.",

keywords = "Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma, R-CHOP",

author = "Mark Lipstein and Owen O'Connor and Francesca Montanari and Luca Paoluzzi and Danielle Bongero and Govind Bhagat",

year = "2010",

month = oct,

doi = "10.3816/CLML.2010.n.074",

language = "English (US)",

volume = "10",

pages = "E43--E46",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "5",

}

TY - JOUR

T1 - Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

AU - Lipstein, Mark

AU - O'Connor, Owen

AU - Montanari, Francesca

AU - Paoluzzi, Luca

AU - Bongero, Danielle

AU - Bhagat, Govind

PY - 2010/10

Y1 - 2010/10

N2 - Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

AB - Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

KW - Diffuse large B-cell lymphoma

KW - Non-Hodgkin lymphoma

KW - R-CHOP

UR - http://www.scopus.com/inward/record.url?scp=79952996426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952996426&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.074

DO - 10.3816/CLML.2010.n.074

M3 - Article

C2 - 21856550

AN - SCOPUS:79952996426

SN - 2152-2650

VL - 10

SP - E43-E46

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 5

ER -

Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this